176 related articles for article (PubMed ID: 27188804)
21. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
22. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
23. Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis.
Ghosh S; Das NK; Mukherjee S; Mukhopadhyay D; Barbhuiya JN; Hazra A; Chatterjee M
Am J Trop Med Hyg; 2015 Oct; 93(4):767-9. PubMed ID: 26175030
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
[TBL] [Abstract][Full Text] [Related]
25. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
[TBL] [Abstract][Full Text] [Related]
26. Corneal complications following Post Kala-azar Dermal Leishmaniasis treatment.
Maruf S; Nath P; Islam MR; Aktar F; Anuwarul A; Mondal D; Basher A
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006781. PubMed ID: 30222747
[TBL] [Abstract][Full Text] [Related]
27. Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform.
Singh-Phulgenda S; Kumar R; Dahal P; Munir A; Rashan S; Chhajed R; Naylor C; Maguire BJ; Siddiqui NA; Harriss E; Rahi M; Alves F; Sundar S; Stepniewska K; Musa A; Guerin PJ; Pandey K
PLoS Negl Trop Dis; 2024 Apr; 18(4):e0011635. PubMed ID: 38626228
[TBL] [Abstract][Full Text] [Related]
28. A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery.
Hasan MM; Proma SB; Hossain MS; Arifuzzaman M; Islam N; Siddique MAB; Amiruzzaman
BMC Infect Dis; 2023 Dec; 23(1):885. PubMed ID: 38110894
[TBL] [Abstract][Full Text] [Related]
29. Post-kala-azar dermal leishmaniasis in Nepal: a retrospective cohort study (2000-2010).
Uranw S; Ostyn B; Rijal A; Devkota S; Khanal B; Menten J; Boelaert M; Rijal S
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1433. PubMed ID: 22206030
[TBL] [Abstract][Full Text] [Related]
30. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
Mukhopadhyay D; Mukherjee S; Ghosh S; Roy S; Saha B; Das NK; Chatterjee M
Int J Dermatol; 2016 May; 55(5):e250-5. PubMed ID: 26536363
[TBL] [Abstract][Full Text] [Related]
31. Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
Ramesh V; Singh R; Avishek K; Verma A; Deep DK; Verma S; Salotra P
PLoS Negl Trop Dis; 2015; 9(10):e0004093. PubMed ID: 26492039
[TBL] [Abstract][Full Text] [Related]
32. Post kala-azar dermal leishmaniasis: an unresolved mystery.
Mukhopadhyay D; Dalton JE; Kaye PM; Chatterjee M
Trends Parasitol; 2014 Feb; 30(2):65-74. PubMed ID: 24388776
[TBL] [Abstract][Full Text] [Related]
33. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM
Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148
[TBL] [Abstract][Full Text] [Related]
34. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
[No Abstract] [Full Text] [Related]
35. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
[TBL] [Abstract][Full Text] [Related]
36. Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis.
Hasnain G; Shomik MS; Ghosh P; Rashid MO; Hossain S; Hamano S; Mondal D
Am J Trop Med Hyg; 2016 Dec; 95(6):1383-1385. PubMed ID: 27672208
[TBL] [Abstract][Full Text] [Related]
37. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
[TBL] [Abstract][Full Text] [Related]
38. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
Goyal V; Das VNR; Singh SN; Singh RS; Pandey K; Verma N; Hightower A; Rijal S; Das P; Alvar J; Bern C; Alves F
PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008429. PubMed ID: 32687498
[TBL] [Abstract][Full Text] [Related]
39. To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL).
Rabi Das VN; Siddiqui NA; Pal B; Lal CS; Verma N; Kumar A; Verma RB; Kumar D; Das P; Pandey K
PLoS One; 2017; 12(3):e0174497. PubMed ID: 28355259
[TBL] [Abstract][Full Text] [Related]
40. Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy.
Belay AD; Asafa Y; Mesure J; Davidson RN
Ann Trop Med Parasitol; 2006 Apr; 100(3):223-7. PubMed ID: 16630379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]